What is the Fiscal Year for TheraCryf?
Date: April 16, 2026
TheraCryf's current fiscal year starts on November 1, 2025, and ends on October 31, 2026. Their current quarter is Q2, which ends on April 30, 2026.
Current Fiscal Year Overview
Fiscal Year Start
November 1, 2025
Fiscal Year End
October 31, 2026
Current Quarter
Q2
Current Quarter End
April 30, 2026
Quarterly Breakdown
Q1
Nov 1, 2025 – Jan 31, 2026
Q2
Feb 1, 2026 – Apr 30, 2026
Q3
May 1, 2026 – Jul 31, 2026
Q4
Aug 1, 2026 – Oct 31, 2026
Company Information
Headquarters
Macclesfield, England, United Kingdom
Industry
Research
Stock Symbol
EVG
Website
https://theracryf.comDescription
TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. Formerly Evgen Pharma plc, the Company acquired Chronos Therapeutics in April 2024. TheraCryf, the new name for the Group, reflects a wider mission and broader portfolio. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like TheraCryf and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.